| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_27aec21a007f44bc4122eed711111058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_114e4423ec77cbc8dab9d0a98909704e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-185
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-351
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-185 |
| filingDate |
2015-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_987edcadcd3e4fae789a01055ab2927a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f60d145f65ee267f4a4db64aeafd31c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27a3ec99425b8d55e01b420dccc6bd74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_352c5206bd2bd45b3fffd58d04af63f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21d7e9773159810191eb55618143517d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d4f90bc452e5fad16aaf8c17418b84a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd7d81dd20014147552bc8e19e61a598 |
| publicationDate |
2017-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017273939-A1 |
| titleOfInvention |
A pharmaceutical composition for the treatment of multi-drug resistant infections |
| abstract |
A pharmaceutical composition for the treatment of multi-drug resistant infections includes an antimicrobial agent in combination the benzopyrano[3,4-b][1]benzopyran-12(6H)-one class of compound boeravinone B of Formula 1: n n n n n n n n n n The bio-efficacy of anti-infective drugs can be potentiated, when used in combination with boeravinone B. Boeravinone B can overcome the resistance or multi-drug resistance developed by bacteria against quinolone, mupirocin and macrolide class of anti-bacterial agents via inhibition of bacterial efflux pumps. Thus, the compositions can be used to treat or prevent drug-resistant bacterial diseases. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112746045-A |
| priorityDate |
2014-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |